

Appendix 4E

Preliminary Final Report

30 June 2024

1. Company Details

INVEX THERAPEUTICS LTD

ABN 29 632 145 334

Report ending
Corresponding period

30 June 2024
30 June 2023

Results for announcement to the market

2. Consolidated Financial Results			June 2024	June 2023
			\$	\$
Other income	Up	37%	1,704,074	1,256,168
Loss after tax attributable to members	down	79%	(1,641,809)	(7,749,856)
Net Loss for the period attributable to members	down	78%	(1,679,357)	(7,731,713)
Net Tangible asset per share (cents)			2.18	10.31

3. Consolidated Statement of Comprehensive Income

Refer to attached Consolidated Financial Report.

4. Consolidated Statement of Financial Position

Refer to attached Consolidated Financial Report.

5. Consolidated Statement of Cashflows

Refer to attached Consolidated Financial Report.

6. Consolidated Statement of Changes in Equity

Refer to attached Consolidated Financial Report.

7. Dividends

The Directors do not propose that Invex Therapeutics Ltd will pay a dividend.

8. Details of Dividend Reinvestment Plan

Not applicable.

9. Details of entities over which control has been gained or lost during the period.

None.



10. Details of associates and joint ventures

Not applicable.

11. Any other significant information needed by an investor to make an informed assessment of the Company's financial performance and financial position

Refer to attached Consolidated Financial Report.

12. Foreign entities

Refer to attached Consolidated Financial Report note 16.

13. Commentary on results and explanatory information

Refer to Director's Report and Review operations in attached Consolidated Financial Report.

14. Audit

The financial statements on which the Consolidated Financial Report is based have been audited.

15. Annual General Meeting

The Company will hold a virtual Annual General Meeting on Tuesday 26 November 2024 at 11.00am WST. Further details will be released to shareholders.

For personal use only



For personal use only

Financial Report
30 JUNE 2024

Contents

1	Chairman's Letter
5	Directors' Report
17	Auditor's Independence Declaration
18	Consolidated Statement of Profit or Loss and Other Comprehensive Income
19	Consolidated Statement of Financial Position
20	Consolidated Statement of Changes in Equity
21	Consolidated Statement of Cash Flows
22	Notes to the Consolidated Financial Statements
38	Consolidated Entity Disclosure Statement
39	Directors' Declaration
40	Independent Auditor's Report
44	Corporate Governance Statement
45	ASX Additional Information
iii	Corporate Directory

For personal use only

Chairman's letter



On behalf of the Board of Invex Therapeutics Ltd (Invex, the Company) and its controlled entity (Group), the Company hereby presents the Invex Annual Report to shareholders for the year ended 30 June 2024 (FY24).

The FY24 year was a challenging one for the Company, with the early closure of the Idiopathic Intracranial Hypertension (IIH) registration-directed Phase III clinical trial for Presendin™, a sustained-release Exenatide formulation that has been shown to lower intracranial pressure, a hallmark of IIH patients. The remainder of the financial year was spent on cost effectively completing the close-out of the trial, restructuring the Company given IIH was the only clinical trial of the Group and maximising a return to shareholders of surplus cash held on the balance sheet for purposes of completing the Phase III trial.

Closure of IIH EVOLVE Phase III Clinical Trial

On 21 August 2023, the Board made the difficult decision, in the interest of all shareholders, to close the trial for new patients with immediate effect and to take the necessary steps to complete an orderly wind down and subsequent close-out of the trial in majority by 31 December 2023 to preserve cash.

IIH-EVOLVE was a placebo-controlled, double-blind trial which aimed to randomise 240 patients with newly diagnosed IIH to determine the efficacy and safety of Presendin™ versus placebo, administered once weekly over 24 weeks. The primary endpoint of the trial was

the change in intracranial pressure from baseline with key secondary endpoints related to vision and headache outcome measures.

The decision to close the trial was taken in response to an independent market assessment which highlighted major future impacts to IIH market opportunity for Presendin™, with current pricing for GLP-1 receptor agonists (GLP-1RA) rendering Presendin™ uneconomic in IIH and achieving a reimbursement premium for Presendin™ for Invex reflective of its orphan drug status becoming a major challenge.

The strategic evaluation of Invex's IIH EVOLVE Phase III clinical trial program investigating Presendin™ (Exenatide - another type of GLP-1RA) was initiated in response to the rapidly evolving market uptake of GLP-1RAs for the treatment of obesity with or without co-morbidities such as type II diabetes, along with a significant late-stage pipeline of new obesity agents in both oral and injectable formats expected to enter the market in coming years.

The link between obesity and IIH is well established. Patients with IIH are typically female, and more than 90% of these sufferers are obese. The primary principle of IIH management is weight loss, which is considered the disease modifying intervention of choice according to the 2018 IIH Consensus Treatment Guidelines. Exenatide does not exhibit the same weight loss characteristics as other GLP-1RAs from the IIH Phase II Pressure trial reported in 2020 and therefore could be at material risk of

obsolescence or substitution in treating IIH patients if regulatory approval and reimbursement was eventually sought by Invex following a clinical trial.

As a result of a number of interviews with independent opinion leaders in IIH and reimbursement representatives in key European markets, along with recommendations provided to Invex, the Board made the decision that the continuation of the trial and the necessary expenditure required to complete recruitment under a revised IIH EVOLVE trial was not viable.

Restructuring

As a result of the premature termination of the trial, the Company restructured its cost base to reflect the reversion to a pre-clinical stage of development for Exenatide in other disorders associated with raised intracranial pressure, including traumatic brain injury (TBI) and glaucoma. The Group's clinical team who were based in the UK and dedicated to the oversight of the IIH Phase III trial were unable to be redirected elsewhere in the Company, and regrettably were made redundant during the financial year. The last UK-based employee completed their employment with Invex on 1 February 2024. The Group is now structured appropriately to progress the Exenatide assets through further pre-clinical development as necessary while also assessing new opportunities to strengthen the Group's pipeline and development potential moving forward. This was in addition to the resignation of the Company's previous UK-based Chairman who was also a key

Chairman's letter continued

For personal use only

scientific consultant to Invex and our UK-based Executive Director / Chief Scientific Officer who held oversight responsibilities of IIH EVOLVE, in early July. The loss of our entire UK team during the financial year resulted in significantly more workload for our small remaining team who were required to take over responsibility of this global trial and provide additional services to Invex to ensure IIH EVOLVE was closed in a cost effective and expeditious manner to preserve cash in the business. I thank them for all their efforts during that difficult period for Invex.

\$14.0 million Equal Access Capital Return

On 1 November 2023, the Company announced a return of \$14.0 million to shareholders representing approximately 19 cents per share, by way of an equal access capital return for the purposes of the Corporations Act. This initiative was in response to the closure of the IIH EVOLVE clinical trial, and the Board's careful assessment of ongoing capital requirements, given the reduced level of clinical trial activity. The return of \$14.0 million considered the discharge of remaining forecast costs relating to the closure of the IIH EVOLVE Phase III clinical trial, while balancing the medium-term funding requirements of Invex's existing programs in TBI and glaucoma, which are at a much earlier stage of development and require significantly less investment.

The Group maintains balance sheet flexibility to continue Invex's existing programs and to explore new strategic opportunities to add value to the Company's core intellectual property.

The Company sought and received shareholder approval at a General Meeting of shareholders on 28 November 2023. The capital return payment was made on 18 December 2023. On 20 March 2024 Invex announced the Australian Taxation Office (ATO) had published a Class Ruling (CR 2024/17) in relation to Invex's \$0.19 per share return of capital.

The ATO Class Ruling confirmed that no part of the capital return would be assessable as a dividend for Australian taxation purposes for Invex shareholders. The tax consequences for a Shareholder with respect to the capital return may vary depending upon the Shareholder's individual circumstances. Shareholders should consult their own tax adviser as to the potential tax consequences for them with respect to the capital return.

New US patent Granted for Exenatide in TBI and European Patent in Hydrocephalus

The Group made solid progress in building out its intellectual property across new therapeutic areas with raised intracranial pressure, including TBI and hydrocephalus. On 23 August 2023, the Group announced the United States Patent and Trademark Office

(USPTO) granted the Group a new US patent entitled "Elevated Intracranial Pressure Treatment" (patent number 11,738,067), covering the use of Exenatide in disorders associated with raised intracranial pressure including additional new claims in brain injury and brain trauma.

On 22 November 2023, the Group announced the Decision to Grant from the European Patent Office for European patent number EP4000630 titled "Elevated intracranial pressure treatment". The patent provides additional claims for the use of Exenatide and other GLP-1 receptor agonists in reducing elevated intracranial pressure (ICP) associated with the treatment of hydrocephalus, normal pressure hydrocephalus or meningitis. Hydrocephalus is a neurological disorder associated with an increased volume of cerebrospinal fluid (CSF) within the cerebral ventricles that typically is associated with increased ICP. The hydrocephalus market was worth US\$3.3 billion globally in 2022.



Receipt of \$1.2 million UK Government R&D Tax Rebate

On 21 June 2024 the Group received £633k (approximately A\$1.2 million) to the Company's wholly owned UK subsidiary from the UK government for eligible R&D expenditures made by Invex during the 2023 financial year. The 2023 financial year represented a significant R&D spend for the Company, predominately associated with the IIH EVOLVE Phase III clinical trial. The funds partially offset gross R&D spend for that year. A further claim for the 2024 financial year is anticipated to be prepared and submitted in the second half of the 2024 calendar year.

Financials

The Group recorded a net loss after tax of \$1.64 million for the year ended 30 June 2024 (FY24), a decrease of 79% on the prior corresponding period (pcp), this was largely due to lower R&D costs of \$2.04 million (FY23: \$7.40 million), reflecting the closure of the the IIH EVOLVE trial, no manufacturing costs of drug product (Presendin™) and placebo from Peptron during the period (FY23: \$0.74 million). In addition, there was also lower share-based payment expenses of \$0.14 million (FY23: \$0.48 million). The corporate and administrations costs were \$1.17 million (FY23: \$1.13 million).

The Group remains in a strong financial position with cash and cash equivalents of \$6.03 million as at 30 June 2024 (FY23: \$22.47 million).

Corporate Governance

There were major changes to the Board composition during the year. On 3 July 2023, the Group announced the resignations of Dr Jason Loveridge, Non-Executive Chairman and Professor Alexandra Sinclair, Executive Director and Chief Scientific Officer, effective 10 July 2023.

The resignations of Dr Loveridge and Professor Sinclair were in response to discussions with major shareholders who indicated to the Company that, following the ASX release on 28 June 2023, they no longer supported their positions as Directors of the Company. Consequently, both Directors felt it was in the best interests of all shareholders to tender their resignations.

Dr Loveridge was Chairman of Invex since March 2019 and Professor Sinclair an Executive Director since June 2019. Both made considerable contributions to the Company, including an Initial Public Offering and listing on the Australian Stock Exchange (ASX) and material development of the Company's therapeutic assets. Professor Sinclair and Dr Loveridge ceased their engagement with the Company in October 2023.

The Board would like to express sincere thanks to Dr Loveridge and Professor Sinclair for their tireless efforts in moving the Exenatide program in IIH into a Phase III clinical trial. Although the early termination of the trial was a difficult decision for the Company both Jason and Alex, as

co-founders of the Company, were passionate advocates for Invex and the research undertaken to find treatments for patients with raised intracranial pressure, including IIH.

On 8 November 2023, the Group announced the appointment of Mr David Wheeler as a Non-Executive Director of the Company, effective 8 November 2023. David has more than 30 years of Senior Executive Management, Directorships, and Corporate Advisory experience. He is a foundation Director and Partner of Pathways Corporate, a boutique Corporate Advisory firm that undertakes assignments on behalf of family offices, private clients, and ASX listed companies. David is a Fellow of the Australian Institute of Company Directors (FAICD).

On 18 June 2024, the Group announced that Dr Megan Baldwin had advised the Group of her decision to retire as a Non-Executive Director of the Company effective 30 June 2024. The Board wishes to sincerely thank Dr Baldwin for her service to Invex where she served as a Non-Executive Director since February 2021. Dr Baldwin was a strong and significant contributor to the Board, joining the Company at a critical point as the Group advanced Exenatide from Phase II to Phase III clinical trials in IIH.

Chairman's letter continued

Concluding Remarks

The 2024 financial year has proven a difficult one for the Company, with the closure of the IIH EVOLVE Phase III clinical trial. The Group is in a strong financial position despite the closure of the trial, as the expenditure was expected to ramp up significantly in FY24 and FY25 as the study expanded clinical sites and completed recruitment.

The Board moved decisively to return surplus capital to shareholders, to expeditiously complete the trial closure process on time and under budget, while examining the potential for new applications of Exenatide in other raised intracranial pressure disorders, including traumatic brain injury and glaucoma.

In addition, the Group continues to assess certain opportunities that may complement Invex's existing intellectual property assets within the neurological field that aims to generate additional shareholder value over time. These discussions remain ongoing.

We look forward to an improved 2025 financial year as the Board seeks to generate additional shareholder value on these strategic priorities.



A handwritten signature in black ink that reads "David McAuliffe". The signature is written in a cursive, slightly stylized font.

Mr David McAuliffe
Non-Executive Chairman

For personal use only

Directors' Report

Your Directors present their report together with the consolidated financial statements of Invex Therapeutics Ltd (Invex or Company) and its controlled entity (Group) for the financial year ended 30 June 2024.

DIRECTORS

The name of the Directors in office for the year ended 30 June 2024 until the date of this report are as follows. All Directors were in office for the entire year unless otherwise stated.

Dr Thomas Duthy

Executive Director

Appointed 1 October 2020

Dr Duthy has over 20 years of direct financial market and executive level/Board experience with ASX listed companies. He is a Director and Founder of Nemean Group, which provides corporate advisory and investor relations (IR) services in the Life Sciences and Technology sectors. This included an IR/Corporate Development consultancy role with Nova Eye Medical (ASX:EYE), during which time a \$100 million all-cash sale of their Lasers & Ultrasound business to Lumibird Group was completed (2020). He has also provided IR advisory services to Limeade (ASX:LME), which announced a \$112 million all cash takeover by WebMD Health Services in June 2023, representing a 325% premium to the prevailing market price.

Prior to establishing Nemean Group in October 2018, Dr Duthy was the Global Head of Investor Relations & Corporate Development at Sirtex Medical Limited (ASX:SRX), which was sold to CDH Investments in September 2018 for A\$1.9 billion and remains the largest medical device transaction in Australian corporate history. Prior to Sirtex, Tom spent ten years as a leading sell-side Healthcare & Biotechnology analyst at Taylor Collison Limited, focused mainly on small cap companies. He is a Member of the Australian Institute of Company Directors (MAICD).

Current directorships - Neurotech International Limited and Arovella Therapeutics Limited

Former directorships held in last three years - PharmAust Limited - resigned 9 May 2024, Respiro Limited - resigned 19 April 2022

Interests in shares and options - 285,661 shares and 500,000 unlisted options

Mr David McAuliffe

Non-Executive Chairman

Appointed 8 March 2019

Mr McAuliffe is an experienced company director and entrepreneur who has had over twenty years' experience, mostly in the international biotechnology field. During that time, he was involved in numerous capital raisings and in-licensing of technologies. He is a founder of several companies in Australia, France and the United Kingdom, many of which have become public companies. Mr McAuliffe has an Honours degree in Law, a Bachelor of Pharmacy degree and is the President of the Dyslexia - Speld Foundation WA (Inc). Mr McAuliffe is considered an independent Director.

Current directorships - 4DS Memory Limited

Former directorships held in last three years - None

Interests in shares and options - 3,350,001 shares

Mr David Wheeler

Non-Executive Director

Appointed 8 November 2023

Mr Wheeler has more than 30 years of Senior Executive Management, Directorships, and Corporate Advisory experience. He is a foundation Director and Partner of Pathways Corporate a boutique Corporate Advisory firm that undertakes assignments on behalf of family offices, private clients, and ASX listed companies. David is a Fellow of the Australian Institute of Company Directors (FAICD).

For personal use only

Directors' Report continued

Current directorships

Non-Executive Chairman – OZZ Resources Ltd from May 2022, Protean Energy Ltd from May 2017, Avira Resources Ltd from September 2018

Non-Executive Director - Ragnar Metals Ltd from December 2017, PVW Resources Limited from August 2017, MOAB Ltd (previously Delecta Ltd) from June 2020, Cycliq Group Ltd from June 2021, Earth Energy Ltd (previously Cardle Resources Ltd) from October 2021, Wellfully Ltd from May 2024

Former directorships held in last three years

Non-Executive Chairman – Blaze International Limited resigned November 2021

Executive Chairman – Health House International Limited resigned May 2023

Non-Executive Director – Syntonic Limited resigned May 2022, Athena Resources Limited resigned September 2022, Color TV Limited resigned September 2023, Tyranna Resources Limited resigned June 2024

Interests in shares and options - Nil

Dr Megan Baldwin

Non-Executive Director

Appointed 16 February 2021 (resigned 30 June 2024)

Dr Baldwin is CEO and Managing Director of Opthea Limited (ASX:OPT; NASDAQ:OPT), a late-stage biopharmaceutical company developing a novel therapy, OPT-302, to address the unmet need in the treatment of retinal eye diseases, including wet age-related macular degeneration (wet AMD). Under Dr Baldwin's leadership, Opthea has rapidly advanced its ophthalmology program through Phase I and Phase II clinical development and in October 2020 completed a \$180 million IPO and listing on the US NASDAQ exchange to progress two pivotal Phase III studies in wet AMD. Dr Baldwin is currently over-seeing the expansion of the company's management team in the US and preparing for commercialization of OPT-302.

Dr Baldwin is an experienced biotechnology executive, having over 20 years' experience working on therapeutic drug development programs for cancer and ophthalmic indications. Prior to Opthea, Dr Baldwin was employed at Genentech (now Roche) as a postdoctoral researcher before moving to Genentech's commercial division. Dr Baldwin also serves on the Board of Ausbiotech as Deputy Chair. Dr Baldwin is considered an independent Director.

Current directorships – Opthea Limited

Former directorships held in last three years – Ausbiotech

Interests in shares and options - 50,000 unlisted options

Ms Narelle Warren

Company Secretary

Ms Warren is a Chartered Accountant with over twenty-five years of corporate advisory, financial management and company secretarial experience. Ms Warren has coordinated and assisted in numerous corporate transactions, including acquisitions, divestments and raising funds via private and public equity markets. She holds both a Bachelor of Laws and Bachelor of Commerce.

PRINCIPAL ACTIVITY

Invex is a biopharmaceutical Group focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye.

Presendin™ is the Group's filed (and granted) trademark name for reformulated Exenatide.

The principal activity of the Group during the year has been to manage the close out of the Phase III IIIH EVOLVE clinical trial and explore new potential applications for Exenatide in TBI and other neurological disorders with raised ICP, consistent with the Group's patents.

OPERATING RESULTS

The result of the Group for the year ended 30 Jun 2024 was a loss of \$1,64 million (2023: \$7.75 million loss). The net loss of the Group predominantly related to Research & Development costs of \$2.04 million (2023: \$7.40 million) associated with the Phase III clinical trial, intellectual property prosecution, administration and corporate costs of \$1.1 million (2023: \$1.125 million) and non-cash items; notably share-based payments of \$0.14 million (2023: \$0.481 million).

REVIEW OF OPERATIONS

During the year, the Group initially focussed on addressing the slower than anticipated recruitment and delay in site activations which impacted the Group's timelines on recruitment into the IIH EVOLVE trial. The Board, having consulted extensively with its regulatory and clinical experts, decided to significantly amend the existing protocol for the IIH EVOLVE trial and sought the requisite authorities' feedback and ethics committee approvals for a revised protocol. Overall, the changes were expected to be cash neutral with respect to the original IIH EVOLVE trial costing, with recruitment anticipated to materially accelerate due to an expected significant reduction in pre-screen and screen failures.

In parallel, the Group engaged a specialised global healthcare intelligence group to undertake an analysis on the potential future risks to the addressable market for Presendin™ for IIH. This comprised a detailed market assessment initiated to understand the risk of approved GLP-1RAs to Invex's IIH market opportunity, given the strong correlation between IIH and obesity in female patients.

However, as a result of the independent analysis of the IIH Market and effects of GLP-1RAs on the Group's core value proposition Presendin™, the Board made the decision that the continuation of the trial (including under a modified protocol) and the necessary expenditure required to complete recruitment under the revised IIH EVOLVE trial, was not viable.

The Company restructured its operations considerably as a result, with the resignation of the key management personnel comprising of Dr Jason Loveridge (Chairman/consultant) and Professor Alex Sinclair (Executive Director and Chief Scientific Officer) in July and who held overall clinical oversight of IIH EVOLVE along with all remaining UK clinical staff who were also made redundant during the financial year. Clinical trial close-out responsibilities for IIH EVOLVE were assumed by the small remaining corporate team in Australia.

For the remainder of the financial year, the Group effectively managed, in a cost and time effective manner, the close-out of the Phase III clinical trial of Presendin™ in IIH and rationalised its operations to reflect the Group's Exenatide pipeline, which following the Phase III closure comprised of pre-clinical stage opportunities in TBI and glaucoma.

The Group retained sufficient funds following the \$14.0 million equal access capital return, for the size and nature of the Group's operations in FY25 and potentially beyond.

LIKELY DEVELOPMENTS

None

EQUAL ACCESS CAPITAL RETURN

A \$14.0 million equal access capital return representing \$0.1863 cents per share was paid to eligible shareholders on 18 December 2023.

DIVIDENDS

No dividends were paid or recommended by the Directors since the commencement of the year.

SIGNIFICANT CHANGES IN STATE OF AFFAIRS

Other than as outlined above, there were no significant changes in the Group's state of affairs during the year.

MATTERS SUBSEQUENT TO THE END OF THE FINANCIAL YEAR

No significant events occurred after balance date which may affect either the Group's operations or results of those operations or the Group's state of affairs.

Directors' Report continued

MEETINGS OF DIRECTORS

During the year the following Director meetings were held.

Director	Board Meetings	
	Number Eligible to Attend	Number Attended
Dr Thomas Duthy	9	9
Mr David McAuliffe	9	9
Mr David Wheeler	5	5
Dr Megan Baldwin	9	9
Dr Jason Loveridge	1	1
Prof Alexandra Sinclair	1	1

ENVIRONMENTAL REGULATIONS

The Group is not subject to significant environmental regulation in respect of its research and development activities.

UNISSUED SHARES UNDER OPTION

Unissued ordinary shares of Invex Therapeutics Ltd under option at the date of this report are as follows:

Date Options Granted	Expiry Date	Exercise Price	Number Under Option
22 November 2022	1 December 2026	\$0.67	550,000
1 December 2022	1 December 2026	\$0.67	560,000
Total			1,110,000

INSURANCE OF OFFICERS AND INDEMNITIES

Invex paid a premium to insure the Directors and Secretary of the Group.

The liabilities insured are legal costs that may be incurred in defending civil or criminal proceedings that may be brought against the officers in their capacity as officers of entities in the Group, and any other payments arising from liabilities incurred by the officers in connection with such proceedings. This does not include such liabilities that arise from conduct involving a wilful breach of duty by the officers or the improper use by the officers of their position or of information to gain advantage for them or someone else or to cause detriment to the Group. It is not possible to apportion the premium between amounts relating to the insurance against legal costs and those relating to other liabilities.

The Group has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the company or any related entity against a liability incurred by the auditor.

During the financial year, the company has not paid a premium in respect of a contract to insure the auditor of the company or any related entity.

PROCEEDINGS ON BEHALF OF THE GROUP

No person has applied to the Court under section 237 of the *Corporations Act 2001* for leave to bring proceedings on behalf of the Group, or to intervene in any proceedings to which the Group is a party, for the purpose of taking responsibility on behalf of the Group for all or part of those proceedings.

No proceedings have been brought or intervened in on behalf of the Group with leave of the Court under section 237 of the *Corporations Act 2001*.

NON-AUDIT SERVICES

The Group may decide to employ its auditor on assignments additional to their statutory audit duties where the auditor's expertise and experience with the Group is important.

During the year, other services were performed in addition to their statutory duties. The details of the amount paid are disclosed in Note 20 of the consolidated financial report.

The directors are satisfied that the provision of non-audit services during the year is compatible with the general standard of independence for auditors imposed by the Corporations Act 2001. The Directors are satisfied that the services disclosed within Note 20 did not compromise the external auditors' independence for the following reasons:

- all non-audit services are reviewed and approved by the Board of Directors prior to commencement to ensure they do not adversely affect the integrity and objectivity of the auditor; and
- the nature of the services provided does not compromise the general principles relating to auditor independence in accordance with APES 110: Code of Ethics for Professional Accountants (including Independence Standards) set by the Accounting Professional and Ethical Standards Board.

AUDITOR'S INDEPENDENCE DECLARATION

A copy of the auditors' independence declaration as required under section 307C of the *Corporations Act 2001* is set out on the page following this Directors' Report.

REMUNERATION REPORT - AUDITED

The remuneration report outlines the remuneration arrangements which were in place during the year and remain in place as at the date of this report, for the Directors and Key Management Personnel of the Group.

The information provided in this remuneration has been audited as required by section 308(3C) of the *Corporations Act 2001*.

KEY MANAGEMENT PERSONNEL

Key Management Personnel are those persons who are responsible for directing and controlling the activities of the Group. The Board has determined that the Key Management Personnel of the Group are the Non-Executive Directors and Executives of Invox, whose details are set out below. The following Key Management Personnel during the period unless otherwise stated were:

Director	Date of appointment/resignation	Role
Dr Jason Loveridge	Appointed 8 March 2019/ Resigned 10 July 2023	Non-Executive Chair
Prof Alexandra Sinclair	Appointed 28 June 2019/ Resigned 10 July 2023	Executive Director
Dr Thomas Duthy	Appointed 1 October 2020	Executive Director
Dr Megan Baldwin	Appointed 16 February 2021/ Resigned 30 June 2024	Non-Executive Director
David McAuliffe	Appointed 8 March 2019	Non-Executive Director
David Wheeler	Appointed 8 November 2023	Non-Executive Director
Narelle Warren	Appointed 8 March 2019	CFO & Company Secretary
Carol Parish	Appointed 1 July 2022/Resigned 1 February 2024	Chief Operating Officer

REMUNERATION POLICIES

The Board has not elected to establish a remuneration committee. Given the size of the current Board, remuneration matters will be considered and approved by the full Board.

The following items will be considered and discussed as deemed necessary at the Board meetings:

- recommend the terms and conditions of employment for the Executive Directors and Senior Officers;
- undertake a review of the Executive Directors' performance, at least annually, including setting with the Executive Directors goals for the coming year and reviewing progress in achieving those goals;
- consider and report on the recommendations of the Executive Directors on the remuneration of all direct reports; and
- develop and facilitate a process for Board and Director evaluation.

Non-Executive Director's remuneration

The compensation of Non-Executive Directors is based on market practice, Director's duties and the level of accountability. The compensation policy is designed to attract and retain competent and suitably qualified Non-Executive Directors and aims to align Director's interests with interests of shareholders. Non-Executive Directors are paid a set fee plus statutory superannuation where appropriate, and are reimbursed for out-of-pocket expenses.

The Chair's fees are determined independently to the fees of Non-Executive Directors based on comparative roles in the external market.

The base fees are reviewed annually and were last reviewed at a recent Board meeting. Non-Executive Directors' fees are determined within an aggregate directors' fee pool limit, which is periodically recommended for approval by shareholders. The current limit stands at \$400,000 per annum and was approved by shareholders at its Annual General Meeting of shareholders in November 2021.

A Director may also be paid fees or other amounts as the Directors determine, if a Director performs special duties or otherwise performs services outside the scope of the ordinary duties of a Director.

Executive remuneration

In determining executive remuneration, the Board aims to ensure that remuneration practices are:

- competitive and reasonable, enabling the Company to attract and retain key talent;
- aligned to the Company's strategic and business objectives and the creation of shareholder value;
- transparent; and
- acceptable to shareholders.

The Executive remuneration framework has three components:

- fixed annual compensation comprising salary or fees and benefits, including superannuation;
- short-term performance incentives; and
- long-term incentives through participation in the Invex Employee Share Option Plan.

Fixed annual compensation

Executives receive their base salary/fees and benefits structured as a total employment cost (TEC) package which may be delivered as a combination of cash and prescribed non-financial benefits at the Executive's discretion.

Executives are offered a competitive base pay that comprises the fixed component of pay and rewards. Independent remuneration consultants provide analysis and advice to ensure base pay is set to reflect the market for a comparable role.

Base pay for Executives is reviewed annually to ensure the Executive's pay is competitive with the market. An Executive's pay is also reviewed on promotion.

There are no guaranteed base pay increases included in any Executive's contract.

There are no short-term incentives outstanding.

No benefits other than noted above are paid to Directors or management except as incurred in normal operations of the business.

Short term incentives

No benefits other than remuneration disclosed in the remuneration report are paid to Directors or management except as incurred in normal operations of the business.

Long term incentives

The Group's current Employee Share Incentive Plan (ESIP) is designed to provide medium and long term incentives for all employees (including Non-Executive and Executive Directors) and to attract and retain experienced Employees, Board Members and Executive Officers and provide motivation to make the Group more successful.

As incentive securities granted to Directors and Employees are considered to represent the value of the services received over the vesting period of the incentive security, the assessed value of the options are recognised and expensed over the vesting period. Incentive securities vesting during the period of issue are fully expensed under the accounting standards.

Other than incentive securities disclosed in the remuneration report there have been no options issued to Directors at the date of this financial report.

Voting and comments made at the Company's 2023 Annual General Meeting (AGM)

At the 2023 AGM, 97.5% of the votes received supported the adoption of the remuneration report for the year ended 30 June 2023. The Company did not receive any specific feedback at the AGM regarding its remuneration practices.

Remuneration consultants

The Group did not engage any remuneration consultants during the year.

The Group may engage independent remuneration consultants should it look to make any changes to Director fee levels to ensure they are in line with market conditions and any decisions are made free from undue influence from members of the Group's Key Management Personnel.

Directors' Report continued

Service agreements

The details of the key terms of the revised remuneration from 1 June 2024 and agreements are set out below:

Name	Term of agreement	Remuneration	Termination benefit
<i>Executive Directors</i>			
Dr Thomas Duthy	Open	\$172,000	Relevant notice periods apply, being 1 months' notice with reason or 3 months without reason.

The relative proportions of remuneration that are linked to performance and those that are fixed are as follows:

Name	Fixed remuneration	Performance based remuneration (%)
	2024	2024
<i>Executive Directors</i>		
Dr Thomas Duthy	339,583	4.94

Non-Executive Directors

On appointment to the Board, all Non-Executive Directors enter into a service agreement with the Company in the form of a letter of appointment. The letter summarises the Board's policies and terms, including compensation, relevant to the Director, and among other things:

- the terms of the Director's appointment, including governance, compliance with the Company's Constitution, committee appointments, and re-election;
- the Director's duties, including disclosure obligations, exercising powers, use of office, attendance at meetings and commitment levels;
- the fees payable, in line with shareholder approval, any other terms, timing of payments and entitlements to reimbursements;
- insurance and indemnity;
- disclosure obligations; and
- confidentiality.

The Non-Executive Director fees as of 30 June 2024 have been agreed as follows:

Name	Term of agreement	Remuneration	Termination benefit
<i>Non-Executive Directors</i>			
David McAuliffe - Non-Executive fee	Shareholder Approval by rotation	\$30,000	Nil
David Wheeler - Non-Executive fee	Shareholder Approval by rotation	\$30,000	Nil

For personal use only

Remuneration of Key Management Personnel

Details of the remuneration of the Directors and the KMP's of the Group are found below:

2024	Short-term employee benefits			Termination benefit	Post-employment benefits	Share-based payments	Total	Performance based
	Cash salary & fees	Cash bonus	Consulting fee					
	\$	\$	\$	\$	\$	\$	\$	%
<i>Non-Executive Directors</i>								
Dr Jason Loveridge	1,667	—	58,370 ³	—	—	36,529	96,566	37.83
Dr Megan Baldwin	55,000	—	—	—	—	(2,715)	52,285	(5.19)
David McAuliffe	57,239	—	—	—	—	—	57,239	—
David Wheeler	36,167	—	—	—	—	—	36,167	—
Total Non-Executive Directors	150,073	—	58,370	—	—	33,814	242,257	13.96
<i>Executives</i>								
Narelle Warren	244,250 ¹	—	—	—	—	9,476	253,726	3.73
Prof Alexandra Sinclair	85,929	—	—	—	1,947	31,963	119,839	26.67
Dr Thomas Duthy	339,583 ²	—	—	—	—	17,645	357,228	4.94
Carol Parish	171,453	—	—	82,204 ⁴	20,419	37,194	311,270	11.95
Total Executives	841,215	—	—	82,204	22,366	96,278	1,042,063	9.23
Total	991,288	—	58,370	82,204	22,366	130,092	1,284,320	10.13

- This amount is in relation to Ms Warren's Company Secretary, Finance and role with the Company and paid by the Company to Concept Biotech Pty Ltd an entity which Narelle Warren and David McAuliffe are shareholders and directors. Additional services amounting to \$90,000 were provided from 10 July by Ms Warren for Company Secretary and Financial services required as a result of restructuring of the Group including managing costs relating to closure of the trial within time and budget and additional responsibilities due to resignation of executives based in the UK.
- This amount is in relation to Dr Duthy's Executive Director role with the Company and paid by the Company to Nemean Group Pty Ltd. Additional services amounting to \$138,750 from 10 July 2023 were provided by Dr Duthy for Executive management services required as a result of restructuring of the Group including managing costs relating to closure of the trial within time and budget and additional responsibilities due to resignation of executives based in the UK.
- This amount is in relation to Dr Loveridge's consulting services with the Company and paid by the Company to Warambi Ltd. Dr Loveridge resigned as a Director on 10 July 2023 and ceased his consultancy on 10 October 2023.
- This amount is relates to statutory and voluntary redundancy payments for termination of Carol Parish's employment with the Company effective 1 February 2024.

2023	Short-term employee benefits		Consulting fee	Leave allowances	Post-employment benefits	Share-based payments	Total	Performance based
	Cash salary & fees	Cash bonus						
	\$	\$	\$	\$	\$	\$	\$	%
<i>Non-Executive Directors</i>								
Dr Jason Loveridge	60,000	—	198,494 ³	—	—	97,470	355,964	27.38
Dr Megan Baldwin	50,000	—	—	—	—	40,780	90,780	44.92
David McAuliffe	50,000	—	—	—	—	—	50,000	—
Total Non-Executive Directors	160,000	—	198,494	—	—	138,250	496,744	27.83
<i>Executives</i>								
Narelle Warren	135,000 ¹	—	—	—	—	36,408	171,408	21.24
Prof Alexandra Sinclair	293,859	—	—	—	5,561	85,286	384,706	22.17
Dr Thomas Duthy	180,000 ²	—	—	—	—	100,721	280,721	35.88
Carol Parish	262,209	—	—	—	49,477	101,673	413,359	24.60
Total Executives	871,068	—	—	—	55,038	324,088	1,250,194	25.90
Total	1,031,068	—	198,494	—	55,038	462,338	1,746,938	26.46

1. This amount is in relation to Ms Warren's Company Secretary, Finance and role with the Company and paid by the Company to Concept Biotech Pty Ltd an entity which Narelle Warren and David McAuliffe are shareholders and directors.

2. This amount is in relation to Dr Duthy's Executive Director role with the Company and paid by the Company to Nemean Group Pty Ltd.

3. This amount is in relation to Dr Loveridge's consulting services with the Company and paid by the Company to Warambi Ltd.

SHARE-BASED COMPENSATION

Incentive Securities

The Company's current Employee Incentive Plan (ESIP) was approved by Shareholders on 25 November 2021. The Incentive Plans are designed to provide medium and long term incentives for all employees (including Non-Executive and Executive Directors) and to attract and retain experienced employees, board members and executive officers and provide motivation to make the Company more successful.

Under the ESIP, participants have not yet been granted incentive securities. Incentive securities only vest if certain milestones are met. Participation in the plan is at the Board's discretion and no individual has a contractual right to participate in the plan or to receive any guaranteed benefit.

Any option may only be exercised after the option has vested and other conditions imposed by the Board have been satisfied. Options were granted under the Employee Share Option Plan(ESOP) for no consideration. Options granted under the ESOP carry no dividend or voting rights. When exercisable, shares allotted pursuant to the exercise of options will be allotted following receipt of relevant documentation and payments will rank equally with all other shares.

As options granted to employees are considered to represent the value of the services received over the vesting period of the options, the assessed value of the options is recognised and expensed over the vesting period. Options vesting during the period of issue are fully expensed under the accounting standards.

During the year to 30 June 2024 there were no unlisted options granted. 8,082,000 options issued to Directors and employees were forfeited due to the vesting conditions being unable to be met.

Details of the share-based component issued during the year included in the remuneration are set out below.

EQUITY INSTRUMENTS HELD BY KEY MANAGEMENT PERSONNEL

Shareholdings

The numbers of shares in the Company held during the year by each Director or KMP of Invex, including their personally related parties are set out below. There were no shares granted during the reporting year as compensation.

2024 Name	Balance at the start of the year	Capital Raising shares subscribed for	Disposals	On Market Purchases/ On appointment	Balance at the end of the year
<i>Directors</i>					
Dr Thomas Duthy	106,923	—	—	178,738	285,661
David McAuliffe	3,350,001	—	—	—	3,350,001
David Wheeler	—	—	—	—	—
Dr Megan Baldwin	—	—	—	—	—
Narelle Warren	200,000	—	—	—	200,000
Dr Jason Loveridge	3,374,426	—	—	—	3,374,426
Prof. Alexandra Sinclair	2,500,000	—	—	—	2,500,000
Carol Parish	—	—	—	—	—
Total	9,531,350	—	—	178,738	9,710,088

Directors' Report continued

Option holdings

The number of options over ordinary shares in the Company held during the year by each Director and KMP of Invex Therapeutics Ltd, including their personally related parties, are set out below.

2024 Name	Balance at the start of the year	Granted as compensation	Forfeited/ Expired	Balance at end of the year	Vested and exercisable	Un-vested	Fair value at grant date
<i>Directors and KMP</i>							
Dr Thomas Duthy	1,800,000	—	(1,300,000)	500,000	250,000	250,000	\$0.21
David McAuliffe	200,000	—	(200,000)	—	—	—	—
Dr Megan Baldwin	600,000	—	(550,000)	50,000	50,000	—	\$0.21
David Wheeler	—	—	—	—	—	—	—
Narelle Warren	848,000	—	(624,000)	224,000	112,000	112,000	\$0.23
Dr Jason Loveridge	2,080,000	—	(2,080,000)	—	—	—	\$0.21
Prof. Alexandra Sinclair	1,920,000	—	(1,920,000)	—	—	—	\$0.21
Carol Parish	1,520,000	—	(1,240,000)	280,000	280,000	—	\$0.23
Total	8,968,000	—	(7,914,000)	1,054,000	692,000	362,000	

LOANS WITH KEY MANAGEMENT PERSONNEL

There were no loans to or from key management personnel during the year ended 30 June 2024.

OTHER TRANSACTIONS WITH KEY MANAGEMENT PERSONNEL

There were no other services provided with key management personnel which are not disclosed.

This is the end of the Remuneration Report.

Signed in accordance with a resolution of the Board of Directors.



David McAuliffe
Non-Executive Chairman
Perth, Western Australia, 22 August 2024

For personal use only

Auditors' Independence Declaration



Tel: +61 8 6382 4600
Fax: +61 8 6382 4601
www.bdo.com.au

Level 9, Mia Yellagonga Tower 2
5 Spring Street
Perth, WA 6000
PO Box 700 West Perth WA 6872
Australia

DECLARATION OF INDEPENDENCE BY ASHLEIGH WOODLEY TO THE DIRECTORS OF INVEX THERAPEUTICS LTD

As lead auditor of Invex Therapeutics Ltd for the year ended 30 June 2024, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
2. No contraventions of any applicable code of professional conduct in relation to the audit.

This declaration is in respect of Invex Therapeutics Ltd and the entity it controlled during the period.

Ashleigh Woodley
Director

BDO Audit Pty Ltd

Perth

22 August 2024

BDO Audit Pty Ltd ABN 33 134 022 870 is a member of a national association of independent entities which are all members of BDO Australia Ltd ABN 77 050 110 275, an Australian company limited by guarantee. BDO Audit Pty Ltd and BDO Australia Ltd are members of BDO International Ltd, a UK company limited by guarantee, and form part of the international BDO network of independent member firms. Liability limited by a scheme approved under Professional Standards Legislation.

For personal use only

Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the year ended 30 June 2024

	Note	2024 \$	2023 \$
Other income	4	1,704,074	1,256,168
Research and development expenditure	5	(2,038,777)	(7,400,491)
Finance, compliance and administration expenses	5	(1,169,604)	(1,124,992)
Share-based payment expenses	17	(137,502)	(480,541)
Loss before income tax from continuing operations		(1,641,809)	(7,749,856)
Income tax expense/benefit	6	—	—
Loss for the year from continuing operations		(1,641,809)	(7,749,856)
Other comprehensive income for the year, net of tax			
<i>Items that may be reclassified subsequently to profit or loss</i>		—	—
Exchange differences on translation of foreign operations, net of tax	10	(37,548)	18,143
Total other comprehensive income for the year, net of tax attributable to members of the Group		(1,679,357)	(7,731,713)
Loss for the year is attributable to:			
Owners of Invex Therapeutics Ltd		(1,679,357)	(7,731,713)
Total comprehensive income for the year is attributable to:			
Owners of Invex Therapeutics Ltd		(1,679,357)	(7,731,713)
Loss per share (cents)	11	(2.18)	(10.31)

The above Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the accompanying notes.

For personal use only

Consolidated Statement of Financial Position

AS AT 30 JUNE 2024

	Note	2024 \$	2023 \$
ASSETS			
Current Assets			
Cash and cash equivalents	7	6,025,068	22,470,243
Other receivables		94,983	333,565
Total Current Assets		6,120,051	22,803,808
TOTAL ASSETS		6,120,051	22,803,808
LIABILITIES			
Current Liabilities			
Trade and other payables	8	431,630	1,572,370
Total Current Liabilities		431,630	1,572,370
TOTAL LIABILITIES		431,630	1,572,370
NET ASSETS		5,688,421	21,231,438
EQUITY			
Contributed equity	9	22,412,270	36,413,432
Reserves	10	2,497,268	2,397,314
Accumulated losses	12	(19,221,117)	(17,579,308)
TOTAL EQUITY		5,688,421	21,231,438

The above Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes.

For personal use only

Consolidated Statement of Changes in Equity

For the year ended 30 June 2024

	Contributed Equity \$	Accumulated Losses \$	Reserves	Total Equity \$
Balance as at 1 July 2023	36,413,432	(17,579,308)	2,397,314	21,231,438
Loss for the year	—	(1,641,809)	—	(1,641,809)
Fx reserve movement	—	—	(37,548)	(37,548)
Total comprehensive (loss) for the year		(1,641,809)	—	(1,641,809)
Share-based payment reserve movement	—	—	137,502	137,502
Capital return	(14,001,162)	—	—	(14,001,162)
Balance as at 30 June 2024	22,412,270	(19,221,117)	2,497,268	5,688,421

	Contributed Equity \$	Accumulated Losses \$	Reserves	Total Equity \$
Balance as at 1 July 2022	36,413,432	(9,829,452)	1,896,903	28,480,883
Loss for the year	—	(7,749,856)	—	(7,749,856)
Fx reserve movement	—	—	19,870	19,870
Total comprehensive (loss) for the year		(7,749,856)	—	(7,749,856)
Share-based payment reserve movement	—	—	480,541	480,541
Issue of share capital, net of transaction costs	—	—	—	—
Balance as at 30 June 2023	36,413,432	(17,579,308)	2,397,314	21,231,438

The above Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes.

For personal use only

Consolidated Statement of Cash Flows

For the year ended 30 June 2024

	Note	2024 \$	2023 \$
CASH FLOWS FROM OPERATING ACTIVITIES			
Payments to suppliers and employees		(4,148,087)	(8,125,307)
R&D Tax rebate		1,212,256	459,085
Interest received		491,818	797,083
Net cash outflow from operating activities	13	(2,444,013)	(6,869,139)
CASH FLOWS USED IN FINANCING ACTIVITIES			
Capital return to shareholders		(14,001,162)	—
Net cash outflow from financing activities		(14,001,162)	—
Net decrease in cash and cash equivalents held		(16,445,175)	(6,869,139)
Cash and cash equivalents at the beginning of the year		22,470,243	29,339,382
Cash and cash equivalents at end of financial year	7	6,025,068	22,470,243

The above Consolidated Statement of Cash Flows should be read in conjunction with accompanying the notes.

For personal use only

Notes to the Consolidated Financial Statements

1. BASIS OF PREPARATION

The financial report is a general purpose financial report that has been prepared in accordance with Australian Accounting Standards, Australian Accounting Interpretations, other authoritative pronouncements of the Australian Accounting Standards Board and the Corporations Act 2001.

Invex Therapeutics Limited is a listed public company, incorporated and domiciled in Australia and is the parent entity. Invex Therapeutics Limited is a for-profit entity for the purpose of preparing the financial statements.

These consolidated financial statements comprise the Company and its controlled entity at the end of, or during the year (together referred to as 'the Group') and were authorised for issue by the Board of Directors.

Australian Accounting Standards set out accounting policies that the AASB has concluded would result in a financial report containing relevant and reliable information about transactions, events and conditions. Compliance with Australian Accounting Standards ensures that the financial statements and notes also comply with International Financial Reporting Standards as issued by the IASB. Material accounting policies adopted in the preparation of this financial report are presented below and have been consistently applied unless otherwise stated.

The financial report has been prepared on an accruals basis and is based on historical costs, modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities.

2. NEW AND AMENDED ACCOUNTING STANDARDS AND INTERPRETATIONS

The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

3. SUMMARY OF ACCOUNTING POLICIES

The following material accounting policies adopted by the Group in the preparation of the financial report, have been consistently applied unless otherwise stated.

(a) Principles of consolidation

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Invex Therapeutics Ltd (Company or Invex) as at 30 June 2024 and the results of all subsidiaries for the year then ended. Invex Therapeutics Ltd and its subsidiary together are referred to in these financial statements as the 'consolidated entity'.

Subsidiaries are all those entities over which the consolidated entity has control. The consolidated entity controls an entity when the consolidated entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the consolidated entity. They are de-consolidated from the date that control ceases.

Intercompany transactions, balances and unrealised gains on transactions between entities in the consolidated entity are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the consolidated entity.

The acquisition of subsidiaries is accounted for using the acquisition method of accounting.

(b) Foreign currency translation

The financial statements are presented in Australian dollars, which is Invex's functional and presentation currency.

Foreign currency transactions

Foreign currency transactions are translated into Australian dollars using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at financial year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss.

Foreign operations

The assets and liabilities of foreign operations are translated into Australian dollars using the exchange rates at the reporting date. The revenues and expenses of foreign operations are translated into Australian dollars using the average exchange rates, which approximate the rates at the dates of the transactions, for the period. All resulting foreign exchange differences are recognised in other comprehensive income through the foreign currency reserve in equity.

The foreign currency reserve is recognised in profit or loss when the foreign operation or net investment is disposed of.

(c) Operating segments

Operating segments are presented using the 'management approach', where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers ('CODM'). The CODM is responsible for the allocation of resources to operating segments and assessing their performance.

(d) Revenue recognition

Revenue is recognised when or as the Group transfers control of goods or services to a customer at the amount at which the Group expects to be entitled. The following specific recognition criteria must also be met before revenue is recognised:

Interest income

Revenue is recognised as the interest accrues (using the effective interest method), which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial instrument to the net carrying amount of the financial asset.

(e) Loans and Receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market and are stated at amortised cost using the effective interest rate method.

At each reporting date, the Group assesses whether there is objective evidence that a financial instrument has been impaired.

(f) Cash and Cash Equivalents

Cash and short-term deposits in the Statement of Financial Position comprise cash at bank and on hand and short-term deposits.

(g) Goods and Services Tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Tax Office. In these circumstances the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense. Receivables and payables in the statement of financial position are shown inclusive of GST.

Cash flows are presented in the statement of cash flows on a gross basis, except for the GST components of investing and financing activities, which are disclosed as operating cash flows.

(h) Trade and other Payables

Trade and other payables represent liabilities for goods and services provided to the Group prior to the period end and which are unpaid. These amounts are unsecured, have 30-60 day payment terms and are measured at amortised cost.

Notes to the Consolidated Financial Statements continued

(i) Share-based payments

Equity-settled and cash-settled share-based compensation benefits are provided to employees.

Equity-settled transactions are awards of shares, or options over shares, that are provided to employees in exchange for the rendering of services. Cash-settled transactions are awards of cash for the exchange of services, where the amount of cash is determined by reference to the share price.

The cost of equity-settled transactions are measured at fair value on grant date. Fair value is independently determined using either the Binomial or Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting conditions that do not determine whether the consolidated entity receives the services that entitle the employees to receive payment. No account is taken of any other vesting conditions.

The cost of equity-settled transactions are recognised as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous periods.

The cost of cash-settled transactions is initially, and at each reporting date until vested, determined by applying either the Binomial or Black-Scholes option pricing model, taking into consideration the terms and conditions on which the award was granted. The cumulative charge to profit or loss until settlement of the liability is calculated as follows:

- during the vesting period, the liability at each reporting date is the fair value of the award at that date multiplied by the expired portion of the vesting period.
- from the end of the vesting period until settlement of the award, the liability is the full fair value of the liability at the reporting date.

All changes in the liability are recognised in profit or loss. The ultimate cost of cash-settled transactions is the cash paid to settle the liability.

(j) Equity, reserves and dividend payments

Share capital represents the fair value of shares that have been issued. Any transaction costs associated with the issuing of shares are deducted from share capital, net of any related income tax benefits.

Dividend distributions payable to equity shareholders are included in other liabilities when the dividends have been approved in a General Meeting prior to the reporting date.

All transactions with owners of the parent are recorded separately within equity.

(k) Research and Development

Research expenditure is recognised as an expense is incurred.

Costs incurred on developments projects (relating to the development and testing of new or improved products) are recognised as intangible assets when it is probable that the project will, after considering its commercial and technical feasibility, be completed and generate future economic benefits and its costs can be measured reliably. The expenditure capitalized comprises all directly attributable costs, including costs of materials, services, direct labour and an appropriate proportion of overheads. Other development expenditures that do not meet these criteria are recognized as an expense as incurred. Development costs previously recognised as an expense are not recognized as an asset in a subsequent period. Capitalised development costs are recorded as intangible assets and amortised from the point at which the asset is ready for use.

(l) Income Tax

Tax expense recognised in profit or loss comprises the sum of deferred tax and current tax not recognised in other comprehensive income or directly in equity.

For personal use only

Current income tax assets and/or liabilities comprise those obligations to, or claims from, the Australian Taxation Office (ATO) and other fiscal authorities relating to the current or prior reporting periods that are unpaid at the reporting date. Current tax is payable on taxable profit, which differs from profit or loss in the financial statements. Calculation of current tax is based on tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period.

Deferred income taxes are calculated using the full liability method on temporary differences between the carrying amounts of assets and liabilities and their tax bases. However, deferred tax is not provided on the initial recognition of goodwill or on the initial recognition of an asset or liability unless the related transaction is a business combination or affects tax or accounting profit. Deferred tax on temporary differences associated with investments in subsidiaries and joint ventures is not provided if reversal of these temporary differences can be controlled by the Group and it is probable that reversal will not occur in the foreseeable future.

Deferred tax assets and liabilities are calculated, without discounting, at tax rates that are expected to apply to their respective period of realisation, provided they are enacted or substantively enacted by the end of the reporting period.

Deferred tax assets are recognised to the extent that it is probable that they will be able to be utilised against future taxable income, based on the Group's forecast of future operating results which is adjusted for significant non-taxable income and expenses and specific limits to the use of any unused tax loss or credit. Deferred tax liabilities are always provided for in full.

Deferred tax assets and liabilities are offset only when the Group has a right and intention to set off current tax assets and liabilities from the same taxation authority.

Changes in deferred tax assets or liabilities are recognised as a component of tax income or expense in profit or loss, except where they relate to items that are recognised in other comprehensive income (such as the revaluation of land) or directly in equity, in which case the related deferred tax is also recognised in other comprehensive income or equity, respectively.

(m) Critical Accounting Estimates and Judgments Required

The directors evaluate estimates and judgments incorporated into the financial report based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the Group.

Research and development expenditure

Distinguishing the research and development phases of a new customized project and determining whether the recognition requirements for the capitalization of development costs are met requires judgement. The Group has expensed all costs relating to research and development expenditure to date on the basis that the capitalisation requirements have not been met.

The Group's consideration of whether its internal projects to develop drugs are in a research phase or development phase involves significant judgement.

The Group considers a project to be in a development phase when the following can be demonstrated:

- The technical feasibility of completing the intangible asset so that it will be available for use or sale;
- There is intention to complete the project;
- The existence of a market to be able to sell output resulting from the project;
- How the intangible asset will generate probable future economic benefits;
- There is adequate technical, financial and other resources available to complete the development and to use or sell the intangible asset; and
- Expenditure attributable to the project can be reliably measured.

Share-based payment transactions

The Group measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined using a Black-Scholes model.

Notes to the Consolidated Financial Statements continued

4. OTHER INCOME

	2024	2023
	\$	\$
R&D Tax rebate	1,212,256	459,085
Interest income	491,818	797,083
	1,704,074	1,256,168

5. LOSS FOR THE YEAR

The loss for the year before income tax includes the following specific expenses:

	2024	2023
	\$	\$
(a) Research and development expenses		
Manufacturing expenses	—	743,560
Phase III Clinical Trial	1,081,424	3,847,049
Employee costs	209,943	292,842
Consultants	284,809	1,789,049
COO costs	274,076	311,687
R&D Consumables	27,434	—
CSO - Executive director fees	87,876	299,421
Patent expenses	73,215	116,883
Total	2,038,777	7,400,491
(b) Administration expenses		
Accounting and company secretarial fees	291,222	148,227
ASX, ASIC and bank fees	44,742	52,623
Executive Director's fees	339,582	180,000
Non-Executive Director's fees	150,055	160,000
Legal fees	29,544	30,769
Rent and office expenses	15,614	28,238
Audit, corporate advice and tax fees	84,041	60,914
Travel and entertainment	58,548	102,913
Insurance	94,603	176,597
Investor relations and PR expenses	15,227	112,368
Share registry and shareholder meetings	36,974	23,536
Other general expenses	—	10,247
Fx (gain)/losses	(2,077)	26,738
Website and IT expenses	11,529	11,822
Total	1,169,604	1,124,992

For personal use only

6. INCOME TAX

	2024 \$	2023 \$
(a) The components of tax expense comprise:		
Current tax		
Deferred tax expense	—	—
Total income tax expense from continuing operations	—	—
Deferred income tax expense included in income tax expense comprises:		
Decrease/(increase) in deferred tax assets	—	—
Decrease/(increase) in deferred tax liabilities	—	—
	—	—
(b) The prima facie tax on profit from ordinary activities before income tax is reconciliation of income tax expense to prima facie tax payable:		
Loss before income tax	(1,641,809)	(7,749,856)
Prima facie tax benefit on loss from ordinary activities before income tax at 30% (2023: 30%)	(492,543)	(2,324,957)
Tax effect of:		
- share-based payments	41,251	144,162
- intellectual property costs	21,965	134,661
- entertainment	3,664	3,651
- R&D consultants	50,583	99,597
- tax differential rate	73,708	703,698
Tax losses and temporary differences not recognised	301,373	1,239,188
Income tax expense/(benefit)	—	—
The applicable weighted average effective tax rate are as follows:	0%	0%
(c) Amounts recognised directly in equity		
Aggregate current and deferred tax arising in the reporting period and not recognised in net loss or other comprehensive income but directly debited or credited to equity.		
Current tax		
Net deferred tax	—	—

For personal use only

Notes to the Consolidated Financial Statements continued

	2024	2023
	\$	\$
(d) Unrecognised Net Deferred tax assets		
Patents	26,278	29,197
Accruals	8,827	10,200
Business related costs	7,291	12,679
Australian tax losses	2,207,205	1,935,421
Unrealised fx losses	11,778	12,401
Foreign tax losses	1,128,935	2,126,555
Capital raising costs in equity	33,222	120,643
Net Deferred tax assets not brought to account	3,423,534	4,247,096

7. CASH AND CASH EQUIVALENTS

	2024	2023
	\$	\$
Cash at bank and on hand	6,025,068	22,470,243
	6,025,068	22,470,243

8. TRADE AND OTHER PAYABLES

	2024	2023
	\$	\$
Trade payables	5,598	1,142,947
Accruals and other payables	426,032	429,423
	431,630	1,572,370

Trade payables are non-interest bearing and are normally settled on 30-day terms.

9. CONTRIBUTED EQUITY

	2024	2024	2023	2023
	\$	Number of shares	\$	Number of shares
Ordinary shares on issue – fully paid	22,412,270	75,153,848	36,413,432	75,153,848
	22,412,270	75,153,848	36,413,432	75,153,848

Holders of ordinary shares are entitled to receive dividends as declared from time to time and are entitled to one vote per share at shareholders meetings. In the event of winding up of the Company ordinary shareholders rank after creditors and are fully entitled to any proceeds of liquidation in proportion to the number and amount paid on the shares held.

Movement in fully paid ordinary shares on issue	2024	2024	2023	2023
	\$	Number of shares	\$	Number of shares
Balance at beginning of financial year	36,413,432	75,153,848	36,413,432	75,153,848
Capital return	(14,001,162)	—	—	—
Balance at end of financial year	22,412,270	75,153,848	36,413,432	75,153,848

10. RESERVES

	2024	2023
	\$	\$
Share-based payment reserve	2,516,674	2,379,172
Foreign currency translation reserve	(19,406)	18,142
	2,497,268	2,397,314

Nature and Purpose of Reserve

The share-based payment reserve records the value of options, performance rights and performance shares issued to the Group's directors, employees, and third parties. The value of the amount disclosed during the year reflects the value of options, performance rights and performance shares issued by the Group.

The Foreign currency translation reserve records exchange differences arising on translation of foreign controlled entities.

Options outstanding at 30 June 2024

The following options over ordinary shares of the Company were granted at reporting date:

Grant Date	Expiry Date	Exercise Price	Balance at start of year	Granted during the year	Exercised during the year	Forfeited during the year	Balance at year end	Vested and exercisable at year end
22 Nov 2019	22 Nov 2023	\$0.60	2,200,000	—	—	(2,200,000)	—	—
20 Oct 2020	20 Oct 2023	\$1.30	400,000	—	—	(400,000)	—	—
18 Nov 2020	18 Nov 2023	\$1.30	800,000	—	—	(800,000)	—	—
8 April 2021	8 April 2024	\$1.10	400,000	—	—	(400,000)	—	—
22 Nov 2022	1 Dec 2026	\$0.67	3,600,000	—	—	(3,050,000)	550,000	300,000
1 Dec 2022	1 Dec 2026	\$0.67	1,792,000	—	—	(1,232,000)	560,000	448,000
			9,192,000	—	—	(8,082,000)	1,110,000	748,000

Reconciliation of movement in Share-based payment reserve:	Number of Options	Value \$
Opening Balance - 1 July 2023		2,379,172
Share-based payment expense in respect to employee options on issue at 30 June 2024	560,000	54,109
Share-based payment expense in respect to Director options on issue at 30 June 2024	550,000	83,393
Closing Balance - 30 June 2024	1,110,000	2,516,674

Notes to the Consolidated Financial Statements continued

11. LOSS PER SHARE

	2024	2023
Basic and Diluted (Loss) per Share - cents	\$	\$
Total basic and diluted loss per share - cents	(2.18)	(10.31)

Basic and diluted loss per share is calculated by dividing the loss for the year attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year.

The following table reflects the loss and share data used in the basic and diluted loss per share:

	2024	2023
	\$	\$
Net loss attributable to members of the Group	(1,641,809)	(7,749,856)
Earnings used in calculating basic and diluted earnings per share from continuing operations	(1,641,809)	(7,749,856)

12. ACCUMULATED LOSSES

	2024	2023
	\$	\$
Opening accumulated losses	(17,579,308)	(9,829,452)
Net loss attributable to members of the Group	(1,641,809)	(7,749,856)
Accumulated losses	(19,221,117)	(17,579,308)

For personal use only

13. RECONCILIATION OF NET CASH FLOWS OPERATING ACTIVITIES TO OPERATING (LOSS) AFTER TAX

	2024	2023
	\$	\$
Loss (after income tax) for the year	(1,641,809)	(7,749,856)
Non-cash items included in profit or loss:		
Share-based payment expenses	137,502	480,541
Unrealised fx reserve movements	(37,547)	19,870
Net changes in working capital:		
Increase in trade and other receivables	238,559	(187,852)
Increase/(decrease) in trade and other payables	(1,140,718)	568,158
Net cash used in operating activities	(2,444,013)	(6,869,139)

Non-cash investing and financing activities disclosed in other notes are:

Share-based payment expense (refer Note 17).

FX reserve movements (refer Note 10).

14. FINANCIAL RISK MANAGEMENT

The Group's principal financial instruments comprise cash, short-term deposits and trade payables.

The Group does not have any derivative instruments at 30 June 2024 and does not speculate in any financial instruments.

Financial Risks

The activities of the Group expose it primarily to the financial risks of interest rate risk, liquidity risk, foreign exchange risk and credit risk. The Board of Directors is responsible for monitoring and managing the financial risks of the Group. The Company Secretary/CFO monitors these risks by the review and analysis of monthly management accounts and other financial data.

Interest Rate Risk

The Group's main interest rate risk arises from cash held on deposit by Australian Financial Institutions. Cash held in term deposits is subject to prevailing variable interest rates and expose the Group to cash flow interest rate risk.

The following table summarises interest rate risk for the Group.

2024	Floating Interest Rate \$	Fixed Interest Rate Maturing		Non- Interest Bearing \$	Total \$
		1 Year or Less \$	1 to 5 Years \$		
Interest-bearing financial instruments					
Cash and cash equivalents	6,025,068	—	—	—	6,025,068
	6,025,068	—	—	—	6,025,068

Notes to the Consolidated Financial Statements continued

2023	Floating Interest Rate \$	Fixed Interest Rate Maturing		Non-Interest Bearing \$	Total \$
		1 Year or Less \$	1 to 5 Years \$		
Interest-bearing financial instruments					
Cash and cash equivalents	22,470,243	—	—	—	22,470,243
	22,470,243	—	—	—	22,470,243

The Group does not rely on the generation of interest on cash at bank to provide working capital and does not consider the exposure to be material to the Group and have therefore not undertaken any further analysis of exposure.

Liquidity Risk

Liquidity risk is the risk that the Group will not be able to meet its financial obligations as they fall due. The Board of Directors manage liquidity risk by continually monitoring cash reserves and cashflow forecasts to ensure that financial commitments can be met as and when they fall due.

The Group's objective is to maintain a balance between continuity of funding and flexibility through the use of equity funding.

The following table details the expected contractual maturity for its non-derivative financial liabilities.

2024	Total \$	1 year or less \$	1 - 5 years \$	5+ years \$
Financial liabilities due				
Trade and other payables	5,598	5,598	—	—
	5,598	5,598	—	—

2023	Total \$	1 year or less \$	1 - 5 years \$	5+ years \$
Financial liabilities due				
Trade and other payables	1,142,947	1,142,947	—	—
	1,142,947	1,142,947	—	—

Credit Risk Exposure

Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Group's cash at bank. The carrying amount of the financial assets on the Statement of Financial Position represents the maximum credit exposure.

All cash and cash equivalents are held with large reputable financial institutions within Australia and therefore credit risk is considered minimal.

	2024 \$	2023 \$
Cash and cash equivalents:		
AA rated	6,025,068	22,470,243

For personal use only

Foreign currency risk

The consolidated entity undertakes certain transactions denominated in foreign currency and is exposed to foreign currency risk through foreign exchange rate fluctuations. Foreign exchange risk arises from future commercial transactions and recognised financial assets and financial liabilities denominated in a currency that is not the entity's functional currency. The risk is measured using sensitivity analysis and cash flow forecasting.

15. RELATED PARTY TRANSACTIONS

Key Management Personnel

There were no key management personnel, other than the directors and the CFO/Company Secretary, during the year ended 30 June 2024.

The names of each person holding the position of director of the Company during the financial year are set out below:

- Dr Jason Loveridge (resigned 10 July 2023)
- Prof. Alexandra Sinclair (resigned 10 July 2023)
- Dr Thomas Duthy
- Mr David Wheeler (appointed 8 November 2023)
- Dr Megan Baldwin (resigned 30 June 2024)
- Mr David McAuliffe
- Ms Narelle Warren
- Ms Carol Parish (terminated 1 February 2024)

Transactions with key management personnel

(i) Total key management personnel remuneration is as follows:

	2024	2023
	\$	\$
Short Term Benefits	1,049,658	1,229,562
Post-Employment Benefits	22,366	55,038
Termination Benefits	82,204	—
Share-based payments	130,092	462,338
	1,284,320	1,746,938

(ii) Nil loans were payable to or receivable from KMPs during or at the end of the financial year.

Unless otherwise stated, none of the transactions incorporate special terms and conditions and no guarantees were given or received.

16. INTERESTS IN SUBSIDIARY

The consolidated financial statements incorporate the assets, liabilities and results of the following wholly-owned subsidiary in accordance with the accounting policy described in note 3:

Name	Principal place of business / Country of incorporation	Ownership interest	
		2024 %	2023 %
Invex Therapeutics Ltd	United Kingdom	100	100

Notes to the Consolidated Financial Statements continued

17. SHARE-BASED PAYMENTS

Share-based payments made during the year ended 30 June 2024 are summarised below.

Recognised Share-based payment expense

	2024 \$	2023 \$
Options granted to Directors as incentive	83,393	324,256
Options granted to Employees as incentive	54,109	156,285
	137,502	480,541

Options granted to Directors and Employees for services

The Group's current Employee Share Option Plan (ESIP) was approved by Shareholders on 25 November 2021. The previous Employee Share Option Plan (ESOP) was approved by the Board of Directors on 20 May 2019 ("incentive Plans"). The Incentive Plans are designed to provide medium and long term incentives for all employees (including Non-executive and Executive Directors) and to attract and retain experienced Employees, Board Members and Executive Officers and provide motivation to make the Group more successful.

Under the previous ESOP, participants have been granted options which only vest if certain milestones are met. Participation in the plan is at the board's discretion and no individual has a contractual right to participate in the plan or to receive any guaranteed benefit.

Any option may only be exercised after the option has vested and other conditions imposed by the board have been satisfied. Options are granted under the ESOP for no consideration. Options granted under the ESOP carry no dividend or voting rights. When exercisable, shares allotted pursuant to the exercise of options will be allotted following receipt of relevant documentation and payments will rank equally with all other shares.

As options granted to employees and directors are considered to represent the value of the services received over the vesting period of the options, the assessed value of the options are recognised and expensed over the vesting period. Options vesting during the year of issue are fully expensed under the accounting standards. There were no new incentive securities granted during the financial year. The total Directors and Employee Options expense for the year is outlined below.

Tranche	Valuation Date	Expiry Date	Exercise Price	Balance at start of year	Granted during the year	Lapsed Cancelled during the year	Vested at year end	Total	Total Share-based payment expense for the year
1	22 Nov 2019	22 Nov 2023	\$0.60	2,200,000	—	(2,200,000)	—	—	—
2	20 Oct 2020	20 Oct 2023	\$1.30	400,000	—	(400,000)	—	—	—
3	18 Nov 2020	18 Nov 2023	\$1.30	800,000	—	(800,000)	—	—	—
4	8 April 2021	8 April 2024	\$1.10	400,000	—	(400,000)	—	—	—
5	22 Nov 2022	1 Dec 2026	\$0.67	3,600,000	—	(3,050,000)	300,000	550,000	83,393
6	1 Dec 2022	1 Dec 2026	\$0.67	1,792,000	—	(1,232,000)	448,000	560,000	54,109
Total				9,192,000	—	(8,082,000)	748,000	1,110,000	137,502

For personal use only

Appropriate values for the options using the Black Scholes Model applying the following inputs.

Tranche	5	6
Exercise price	\$0.87	\$0.87
Expected volatility	60%	60%
Expiry date (years)	4.18	4.00
Expected dividends	Nil	Nil
Risk free rate	3.86%	3.86%
Value per option	\$0.21	\$0.23

The vesting conditions attached to the Tranche 5 and 6 Director and Employee Options are as follows:

- 25% of the Options will vest and become exercisable upon completion of 12 months continuous service from date of issue; and
- 25% of the Options vest and become exercisable upon completion of 24 months continuous service from date of issue.
- 25% of the Options vest and become exercisable completion of recruitment for Phase III clinical trial.
- 25% of the Options vest upon completion at the phase 3 clinical trial read out.

The weighted average remaining contractual life of options outstanding at the end of the year was 2.41 years.

18. MATTERS SUBSEQUENT TO END OF FINANCIAL YEAR

There are no matters or events have arisen since the end of the financial period which significantly affected or may significantly affect the operations of the company, the results of those operations or the state of affairs of the company in subsequent financial periods.

For personal use only

Notes to the Consolidated Financial Statements continued

19. PARENT ENTITY INFORMATION

Set out below is the supplementary information about the parent entity.

Statement of profit or loss and other comprehensive income

	Parent	
	2024 \$	2023 \$
Loss after income tax	(3,514,395)	(7,160,991)
Total comprehensive income	(3,514,395)	(7,160,991)

Statement of financial position

	Parent	
	2024 \$	2023 \$
Total current assets	4,916,320	22,367,406
Total non-current assets	—	—
Total current liabilities	410,718	446,203
Total liabilities	410,718	446,203
Equity		
Issued capital	22,412,270	36,413,432
Reserves	2,497,268	2,397,313
Accumulated losses	(20,403,936)	(16,889,542)
Total equity	4,505,604	21,921,203

20. AUDITOR'S REMUNERATION

	2024 \$	2023 \$
Amounts paid or payable to BDO for:		
Audit services		
- an audit or review of the financial report of the entity	41,291	42,414
Total audit services	41,291	42,414
Corporate advisory services	—	2,500
Taxation services	14,800	4,000
Total other services	14,800	6,500

The BDO entity performing the audit of the group transitioned from BDO Audit (WA) to BDO Audit Pty Ltd on 19 April 2024. The disclosures include amounts received or due and receivable by BDO Audit (WA) Pty Ltd, BDO Audit Pty Ltd and their respective related entities.

For personal use only

21. DIVIDENDS

There are no dividends paid or payable at 30 June 2024.

22. COMMITMENTS

There are no other commitments which require disclosure as at 30 June 2024 (30 June 2023: nil).

23. SEGMENT REPORTING

The Group has identified its operating segments based on the internal reports that are reviewed and used by the Board of Directors in assessing performance and determining the allocation of resources.

The Group is managed primarily on the basis of its research and development activities. Operating segments are therefore determined on the same basis.

Reportable segments disclosed are based on aggregating operating segments where the segments are considered to have similar economic characteristics.

The Group operated in one segment which is research and development activities within Australia. The Company is domiciled in Australia.

24. CONTINGENT LIABILITIES AND CONTINGENT ASSETS

The Directors are not aware of any contingent liabilities or contingent assets which require disclosure as at 30 June 2024 (30 June 2023 : nil).

Consolidated Entity Disclosure Statement

Name of entity	Type of entity	Trustee, partner or participant in joint venture	% of share capital held	Country of Incorporation	Australian or foreign resident	Foreign tax jurisdiction of foreign resident
Invex Therapeutics Ltd	Body Corporate	—	N/A	Australia	Australian	N/A
Invex Therapeutics Ltd	Body Corporate	—	100	United Kingdom	Foreign	United Kingdom

For personal use only

Directors' Declaration

In the Directors' opinion:

- (a) the financial statements and notes are in accordance with the *Corporations Act 2001*, and:
- (i) complying with Accounting Standards, the *Corporations Regulations 2001* and other mandatory professional reporting requirements; and
 - (ii) give a true and fair view of the financial position as at 30 June 2024 and of the performance for the year ended on that date of the Group.
 - (iii) are in accordance with International Financial Reporting Standards issued by the International Accounting Standards Board, as stated in note 1 to the financial statements; and
- (b) In the Directors' opinion, there are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and payable;
- (c) The consolidated entity disclosure statement, as set out on page 41, is in accordance with the *Corporations Act 2001*, and is true and correct as at 30 June 2024; and
- (d) The Directors have been given the declarations by the Executive Director as required by section 295A, of the *Corporations Act 2001*.

This declaration is made in accordance with a resolution of the Board of Directors and is signed for and on behalf of the directors by;



David McAuliffe
Non-Executive Chairman

Perth, Western Australia, 22 August 2024

Independent Auditor's Report



Tel: +61 8 6382 4600
Fax: +61 8 6382 4601
www.bdo.com.au

Level 9, Mia Yellagonga Tower 2
5 Spring Street
Perth, WA 6000
PO Box 700 West Perth WA 6872
Australia

INDEPENDENT AUDITOR'S REPORT

To the members of Invex Therapeutics Ltd

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of Invex Therapeutics Ltd (the Company) and its subsidiary (the Group), which comprises the consolidated statement of financial position as at 30 June 2024, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the financial report, including material accounting policy information, the consolidated entity disclosure statement and the directors' declaration.

In our opinion the accompanying financial report of the Group, is in accordance with the *Corporations Act 2001*, including:

- (i) Giving a true and fair view of the Group's financial position as at 30 June 2024 and of its financial performance for the year ended on that date; and
- (ii) Complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the Financial Report* section of our report. We are independent of the Group in accordance with the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's *APES 110 Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

BDO Audit Pty Ltd ABN 33 134 022 870 is a member of a national association of independent entities which are all members of BDO Australia Ltd ABN 77 050 110 275, an Australian company limited by guarantee. BDO Audit Pty Ltd and BDO Australia Ltd are members of BDO International Ltd, a UK company limited by guarantee, and form part of the international BDO network of independent member firms. Liability limited by a scheme approved under Professional Standards Legislation.

For personal use only



Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Share-based Payments

Key audit matter	How the matter was addressed in our audit
<p>In prior years, the Company issued equity instruments to key management personnel (“KMP”). These instruments constitute share-based payments and accordingly are required to be recognised at their fair value and expensed over the respective vesting (performance) period.</p> <p>During the year some share-based payments are continuing to vest and some are to be reversed due to failure to meet milestones.</p> <p>Given the complexities and significant judgements involved under the applicable accounting standard, there is a risk that share based payments have been incorrectly valued or expensed and has thusly been recognised as a key audit matter.</p>	<p>As a result of the risk identified, for all share-based payment transactions continuing to vest during the year we have performed the following audit procedures:</p> <ul style="list-style-type: none"> • Reviewed the relevant agreements to obtain an understanding of the contractual nature and terms and conditions of the share-based payment arrangements; • Held discussions with management to understand the share-based payment treatments in place; • Verified the share-based payment expense has been recognised appropriately according to the vesting conditions; • Verified, where applicable, previous share-based payment expenses have been reversed where the vesting condition has failed to be achieved; and • Reviewed the adequacy of the related disclosures in the financial statements.



Other information

The directors are responsible for the other information. The other information comprises the information in the Group's annual report for the year ended 30 June 2024, but does not include the financial report and the auditor's report thereon.

Our opinion on the financial report does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the directors for the Financial Report

The directors of the Company are responsible for the preparation of:

- a) the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and
- b) the consolidated entity disclosure statement that is true and correct in accordance with the Corporations Act 2001, and

for such internal control as the directors determine is necessary to enable the preparation of:

- i) the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and
- ii) the consolidated entity disclosure statement that is true and correct and is free of misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or has no realistic alternative but to do so.



Auditor’s responsibilities for the audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website (<http://www.auasb.gov.au/Home.aspx>) at:

https://www.auasb.gov.au/admin/file/content102/c3/ar1_2020.pdf

This description forms part of our auditor’s report.

Report on the Remuneration Report

Opinion on the Remuneration Report

We have audited the Remuneration Report included in pages 9 to 16 of the directors’ report for the year ended 30 June 2024.

In our opinion, the Remuneration Report of Invex Therapeutics Ltd, for the year ended 30 June 2024, complies with section 300A of the *Corporations Act 2001*.

Responsibilities

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

BDO Audit Pty Ltd

Ashleigh Woodley
Director

Perth, 22 August 2024

Corporate Governance Statement

In fulfilling its obligations and responsibilities to its various stakeholders, the Board is a strong advocate of corporate governance. This statement outlines the principal corporate governance procedures of Invex Therapeutics Ltd (Group). The Board of Directors (Board) supports a system of corporate governance to ensure that the management of Invex Therapeutics Ltd is conducted to maximise shareholder wealth in a proper and ethical manner.

ASX CORPORATE GOVERNANCE COUNCIL RECOMMENDATIONS

The Board has adopted corporate governance policies and practices consistent with the ASX Corporate Governance Council's *Principles of Good Corporate Governance and Best Practice Recommendations* ("ASX Principles and Recommendations 4th Edition") where considered appropriate for Invex Therapeutics Ltd size and nature. Such policies include, but are not limited to the Board Charter, Board Committee Charters, Code of Conduct, Trading in Securities, Continuous Disclosure, Shareholder Communication and Risk Management Policies.

Further details in respect to the Group's corporate governance practises and copies of Group's corporate governance policies and the 2024 Corporate Governance Statement, approved by the Board and applicable as at 30 June 2024 are available of the Group's website:

<https://invextherapeutics.com/corporate-governance/>

For personal use only

ASX Additional Information

Additional information required by the ASX Limited Listing Rules not disclosed elsewhere in this Annual Report is set out below.

1. SHAREHOLDINGS

The issued capital of the Company as at 1 August 2024 is 75,153,848 ordinary fully paid shares. All issued ordinary fully paid shares carry one vote per share.

Ordinary Shares

Shares Range	Holders	Units	%
1-1,000	189	106,913	0.14
1,001-5,000	379	1,019,918	1.36
5,001-10,000	175	1,364,827	1.82
10,001-100,000	314	10,939,893	14.56
100,001 and above	84	61,722,297	82.13
Total	1,141	75,153,848	100.00

Unmarketable parcels

There were 629 holders of less than a marketable parcel of ordinary shares representing a total of 1,491,232 shares.

2. TOP 20 SHAREHOLDERS AS AT 1 AUGUST 2024

Name	Number of shares	%
1 MINDEROO GROUP PTY LTD	5,000,000	6.65
2 CELTIC CAPITAL PTE LTD <INVESTMENT 1 A/C>	4,450,000	5.92
3 TATTARANG PTY LTD <FORREST FM INV-PEEPINGEE A/C>	3,846,154	5.12
4 TISIA NOMINEES PTY LTD <THE HENDERSON FAMILY A/C>	3,725,000	4.96
5 MR JASON LOVERIDGE	3,374,462	4.49
6 MR DAVID JERIMIAH MCAULIFFE <THE LAZY D9M INVESTMENT A/C>	3,225,001	4.29
7 JK NOMINEES PTY LTD <THE JK A/C>	2,750,000	3.66
8 PROF ALEXANDRA JEAN SINCLAIR	2,500,000	3.33
9 SUNSET CAPITAL MANAGEMENT PTY LTD <SUNSET SUPERFUND A/C>	2,390,000	3.18
10 MRS KATHRYN MARY SALKILLD	2,293,000	3.05
11 BANNABY INVESTMENTS PTY LIMITED <BANNABY SUPER FUND A/C>	1,625,000	2.16
12 PORJED PTY LTD <DEPORJ A/C>	1,600,000	2.13
13 ROCK THE POLO PTY LTD <ROCK THE POLO A/C>	1,400,000	1.86
14 OAKTONE NOMINEES PTY LTD <THE GRIST INVESTMENT A/C>	1,338,518	1.78
15 CITYSCAPE ASSET PTY LTD <CITYSCAPE FAMILY A/C>	1,150,000	1.53
16 CABLETIME PTY LTD <INGODWE A/C>	1,120,000	1.49
17 MR ANDREW CLAYTON <THE KING CAREY A/C>	1,000,000	1.33
18 HAMMERHEAD HOLDINGS PTY LTD <HHH S/F A/C>	1,000,000	1.33
19 MR ANTHONY DE NICOLA & MRS TANYA LOUISE DE NICOLA <DE NICOLA FAMILY S/F A/C>	750,000	1.00
20 ENDLESS SUMMER (WA) PTY LTD <PETER NELSON SUPER FUND A/C>	750,000	1.00
TOP 20 TOTAL	45,537,134	59.26
TOTAL REMAINING HOLDERS BALANCE	29,616,714	40.74
TOTAL	75,153,848	100.00

ASX Additional Information continued

3. UNQUOTED SECURITIES

The unlisted options over shares in the Company as at 1 August 2024 are as follows:

Holder	Number of options held	% of issued capital held
CIPA INVESTMENTS PTY LTD <CIPA INVESTMENTS A/C>	500,000	45.04
GAJA HOLDINGS PTY LTD	50,000	4.50
EMMA HILTON	56,000	5.04
CAROL PARISH	280,000	25.23
PHILUCHNA PTY LTD <PM & NA WARREN FAMILY A/C>	224,000	20.18
Total	1,110,000	100.00

4. VOTING RIGHTS

See note 12 of the financial statements.

5. SUBSTANTIAL SHAREHOLDERS AS AT 1 AUGUST 2024

Holder	Number of shares held	% of issued capital held
TATTARANG	8,846,154	11.77
Mr Jason Peterson and related entities	7,990,000	10.63

6. RESTRICTED SECURITIES SUBJECT TO ESCROW PERIOD

There are no restricted securities.

7. ON-MARKET BUYBACK

There is currently no on-market buyback program for any of Invex's listed securities.

8. COMPANY CASH AND ASSETS

In accordance with Listing Rule 4.10.19, the Company confirms that it has been using the cash and assets it had acquired at the time of admission and for the year ended 30 June 2024 in a way that is consistent with its business objective and strategy.

For personal use only

Corporate Directory

This financial report includes the consolidated financial statements and notes of the Group consisting of Invex Therapeutics Ltd and its controlled entity (Invex Therapeutics UK).

The Group's functional and presentation currency is Australian Dollars (\$).

A description of the Group's operations and principal activities is included in the review of operations and activities in the Directors' report on pages 7 to 18. The Directors' Report is not part of the Consolidated Financial Report.

Directors:

Dr Thomas Duthy
Dr Megan Baldwin (resigned 30 June 2024)
Mr David McAuliffe
Dr Jason Loveridge (resigned 10 July 2023)
Professor Alexandra Sinclair (resigned 10 July 2023)
Mr David Wheeler (appointed 8 November 2023)

Company Secretary:

Ms Narelle Warren

Registered Office & Principal Place of Business:

Level 2, 38 Rowland Street
Perth WA 6008
Tel: +61 8 6382 0137

Website: www.invextherapeutics.com

Auditors:

BDO Audit Pty Ltd
Level 9
Mia Yellagonga Tower 2
5 Spring Street
Perth WA 6000

Bankers:

Westpac Banking Corporation
Level 4 Tower 2 Brookfield Place
123 St Georges Terrace
Perth WA 6000

Solicitors:

Steinepreis Paganin
Level 4, The Read Buildings
16 Milligan Street
Perth WA 6000

Share Registry:

Automic Registry Services
Telephone: 1300 288 664
International: +61 2 9698 5414
Website: www.automicgroup.com.au
ASX code: IXC

For personal use only

For personal use only

